Clinical Trials Sponsored by Nordic Bioscience A/S

Total 1541 results

Novo Nordisk A/S

Completed

A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Healthy Volunteers Diabetes Mellitus, Type 2 | Healthy Volunteers Overweight | Healthy Volunteers Obesity

Netherlands
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (guardian TM 7)

Congenital Bleeding Disorder | Haemophilia A

China
Novo Nordisk A/S

Completed

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes (LIRA-PRIME)

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Serbia, Turkey, Russian Federation, India, Latvia, Puerto Rico, Lebanon, Colombia
Novo Nordisk A/S

Completed

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Novo Nordisk A/S

Completed

An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes (CAPTURE-IO)

Diabetes Mellitus, Type 2

Israel, Japan, Mexico, Argentina, Turkey, Australia, Algeria, Saudi Arabia, Brazil, China
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (guardian™ 5)

Congenital Bleeding Disorder | Haemophilia A

Italy, Sweden, Netherlands, Austria, Spain, United States, Switzerland, Germany, France, Hungary, Greece, Slovenia, Czechia, Slovakia, Poland
Novo Nordisk A/S

Completed

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

Obesity | Metabolism and Nutrition Disorder

United States, Russian Federation, Sweden, Belgium, Mexico
Novo Nordisk A/S

Completed

A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea

Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Obesity | Metabolism and Nutrition Disorder

United States, Israel, Russian Federation, United Kingdom, Canada, Belgium, Germany, Australia
Novo Nordisk A/S

Completed

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin (SCALE™ Insulin)

Obesity | Metabolism and Nutrition Disorder

United States, Israel, Italy, Mexico, Canada, Germany, Turkey
Novo Nordisk A/S

Completed

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus (CAN-TREAT)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Canada
Novo Nordisk A/S

Completed

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Terminated

A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Obesity | Overweight

Germany
Novo Nordisk A/S

Completed

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study (mentor™6)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

Spain, United States, Canada, Italy, United Kingdom, Hungary
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (SUSTAIN™ 4)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, United Kingdom, France, Argentina, South Africa, Germany, Slovenia, Netherlands, Romania, North Macedonia, Mexico, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (SUSTAIN™1)

Diabetes Mellitus, Type 2 | Diabetes

United States, United Kingdom, Mexico, Russian Federation, Japan, Canada, Italy, South Africa, Romania
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects

Healthy | Diabetes

China
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Austria
Novo Nordisk A/S

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Austria, Sweden, Spain, Switzerland, United Kingdom, Germany, Malaysia, Denmark, South Africa, Thailand, Italy
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Poland, Croatia, Germany, Turkey, Slovakia, Bulgaria, Romania, Algeria, Czechia, Ukraine
Novo Nordisk A/S

Completed

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Diabetes

India, Serbia, Bulgaria, Australia, Korea, Republic of, Thailand, Turkey, United Arab Emirates, Hungary
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (SUSTAIN™)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States, Serbia, Malaysia, Thailand, Greece, Japan, Romania
Novo Nordisk A/S

Completed

A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes (DUAL™ II)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Denmark, Hungary, Slovenia, Switzerland, Bulgaria
Novo Nordisk A/S

Completed

A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan, Malaysia, Taiwan, Korea, Republic of, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

India, Denmark, Sweden, Malaysia, Poland, Turkey, Finland, Australia, Thailand, Taiwan
Novo Nordisk A/S

Completed

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Romania, Slovakia, Israel, Saudi Arabia, India, Malaysia, Mexico, Russian Federation, Germany, Croatia, Poland, Serbia, Bulgaria, Canada, Slovenia, Sweden, Denmark, Hungary, Argentina, Austria, Finland, Lebanon, Czechia, Netherlands
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Inflammation | Rheumatoid Arthritis

United States, Mexico, Russian Federation, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Poland, Ukraine, Hungary
Novo Nordisk A/S

Terminated

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE) (ACTION to HOPE)

Haemophilia A, Haemophilia B, Obesity

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United States, Sweden, Serbia, Turkey, United Kingdom, Malaysia, Brazil, Former Serbia and Montenegro, Japan, South Africa
Novo Nordisk A/S

Completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Hungary, Czechia
Novo Nordisk A/S

Completed

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Malaysia, Germany, Algeria, Turkey
Novo Nordisk A/S

Completed

Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

India
Novo Nordisk A/S

Completed

A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Obesity | Metabolism and Nutrition Disorder

United States, Poland, Israel, Italy, Mexico, Spain, Canada, Denmark, Finland, United Kingdom, France, Netherlands, Austria, Belgium, Argentina, Russian Federation, Serbia, Turkey, Switzerland, Germany, South Africa, Hungary, Hong Kong and more
Novo Nordisk A/S

Completed

A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.

Healthy

Germany
Novo Nordisk A/S

Completed

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Obesity | Metabolism and Nutrition Disorder

United States, India, Israel, Italy, United Kingdom, Spain, France, Sweden, Taiwan, Turkey, Germany, South Africa, Puerto Rico
Novo Nordisk A/S

Completed

Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Obesity | Diabetes | Metabolism and Nutrition Disorder

United Kingdom
Novo Nordisk A/S

Completed

The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes

Obesity | Metabolism and Nutrition Disorder

Spain, Denmark, Sweden, Belgium, Finland, Netherlands, United Kingdom, Czechia
Novo Nordisk A/S

Completed

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy (DUAL™IV)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Puerto Rico, Germany, Turkey, Canada, Bulgaria
Novo Nordisk A/S

Completed

Observational Prospective Study on Patients Treated With Norditropin®

Chronic Kidney Disease | Turner Syndrome | Noonan Syndrome | Chronic Renal Insufficiency | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency | Genetic Disorder | Foetal Growth Problem | Small for Gestational Age

Israel, Saudi Arabia, Spain, Argentina, Russian Federation, Germany, Netherlands, Italy, Belgium, United Kingdom, Slovenia, Ireland, Sweden, Denmark, Hungary, Finland, Norway, France, Czechia, Lithuania, Luxembourg, Serbia, Switzerland
Novo Nordisk A/S

Completed

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany

Clinical Trials Sponsored by Nordic Bioscience A/S

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations